Group One Trading, L.P. Cyclerion Therapeutics, Inc. Transaction History

Group One Trading, L.P.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.43 - $0.9 $214 - $449	-499 Reduced 4.4%	10,842 $4,000
Q4 2022 Feb 09, 2023	SELL	$0.42 - $18.8 $2,783 - $124,587	-6,627 Reduced 36.88%	11,341 $7,000
Q3 2022 Nov 09, 2022	SELL	$0.58 - $18.2 $231 - $7,280	-400 Reduced 2.18%	17,968 $15,000
Q2 2022 Aug 11, 2022	BUY	$0.47 - $1.29 $47 - $129	100 Added 0.55%	18,368 $10,000
Q1 2022 May 12, 2022	SELL	$0.96 - $1.78 $7,008 - $12,994	-7,300 Reduced 28.55%	18,268 $20,000
Q4 2021 Feb 11, 2022	SELL	$1.56 - $2.99 $13,104 - $25,116	-8,400 Reduced 24.73%	25,568 $44,000
Q3 2021 Nov 12, 2021	BUY	$2.73 - $4.13 $67,851 - $102,647	24,854 Added 272.7%	33,968 $104,000
Q2 2021 Aug 10, 2021	BUY	$2.18 - $4.29 $3,662 - $7,207	1,680 Added 22.6%	9,114 $36,000
Q1 2021 May 12, 2021	BUY	$2.69 - $5.12 $16,909 - $32,184	6,286 Added 547.56%	7,434 $21,000
Q4 2020 Feb 10, 2021	BUY	$2.25 - $7.12 $2,250 - $7,120	1,000 Added 675.68%	1,148 $4,000
Q3 2020 Nov 12, 2020	SELL	$3.46 - $8.39 $563 - $1,367	-163 Reduced 52.41%	148 $1,000
Q1 2020 May 13, 2020	BUY	$2.46 - $5.84 $765 - $1,816	311 New	311 $1,000

293K

Ticker CYCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,479,800
Market Cap $126M
Description
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of...

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

Stay updated on Group One Trading, L.P. with notifications on news.